PTK2
Focal adhesion kinase 1
As of the edition of 20 October 2026, PTK2 (focal adhesion kinase 1, UniProt Q05397) has 10 drugs tested at it and 11 companies on the list, 2 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q05397
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 41
- Disease areas
- Cancer; Hormones; Digestive system; Lungs and airways; Urinary and reproductive; Pregnancy and women's health; Blood and lymph; Heart and blood vessels
- Registered trials of its drugs
- 77
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 4 |
| Went quiet | 2 |
| Stopped | 2 |
| Status not established | 1 |
| Total | 10 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Defactinib | Marketed | Phase 3 | none listed |
| Ifebemtinib | Active | Phase 3 | none listed |
| ESK-001 | Stopped | Phase 2 | none listed |
| GSK-2256098 | Active | Phase 2 | none listed |
| VS-4718 | Stopped | Phase 1 | none listed |
| APG-2449 | Active | Phase 1 | none listed |
| Narmafotinib | Active | Phase 2 | none listed |
| CEP-37440 | Went quiet | Phase 1 | none listed |
| Conteltinib | Status not established | Phase 2 | none listed |
| PF-00562271 | Went quiet | Phase 1 | none listed |
10 of 10 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Engaged | 8 |
| Undetermined | 1 |
| Total on the list | 11 |
The other 9 companies at PTK2
In the product11 companies in all; 9 are not named here, and no score is.
See the 11 companies at PTK2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.